Orlandi F - Search Results

1

Imaging Properties and Tumor Targeting of ⁶⁸Ga-NeoBOMB1, a Gastrin-Releasing Peptide Receptor Antagonist, in GIST Patients.

Gruber L, Decristoforo C, Uprimny C, Hohenberger P, Schoenberg SO, Orlandi F, Mariani MF, Manzl C, Kasseroler MT, Tilg H, Zelger B, Jaschke WR, Virgolini IJ. Gruber L, et al. Among authors: orlandi f. Biomedicines. 2022 Nov 11;10(11):2899. doi: 10.3390/biomedicines10112899. Biomedicines. 2022. PMID: 36428467 Free PMC article.

2

Targeting Gastrointestinal Stromal Tumor with ⁶⁸Ga-Labeled Peptides: An In Vitro Study on Gastrointestinal Stromal Tumor-Cell Lines.

Paulmichl A, Summer D, Manzl C, Rangger C, Orlandi F, Niedermoser S, Taguchi T, Wängler B, Decristoforo C. Paulmichl A, et al. Among authors: orlandi f. Cancer Biother Radiopharm. 2016 Oct;31(8):302-310. doi: 10.1089/cbr.2016.2092. Cancer Biother Radiopharm. 2016. PMID: 27754750

3

MITIGATE-NeoBOMB1, a Phase I/IIa Study to Evaluate Safety, Pharmacokinetics, and Preliminary Imaging of ⁶⁸Ga-NeoBOMB1, a Gastrin-Releasing Peptide Receptor Antagonist, in GIST Patients.

Gruber L, Jiménez-Franco LD, Decristoforo C, Uprimny C, Glatting G, Hohenberger P, Schoenberg SO, Reindl W, Orlandi F, Mariani M, Jaschke W, Virgolini I. Gruber L, et al. Among authors: orlandi f. J Nucl Med. 2020 Dec;61(12):1749-1755. doi: 10.2967/jnumed.119.238808. Epub 2020 Apr 24. J Nucl Med. 2020. PMID: 32332143 Free article. Clinical Trial.

4

68Ga/177Lu-NeoBOMB1, a Novel Radiolabeled GRPR Antagonist for Theranostic Use in Oncology.

Dalm SU, Bakker IL, de Blois E, Doeswijk GN, Konijnenberg MW, Orlandi F, Barbato D, Tedesco M, Maina T, Nock BA, de Jong M. Dalm SU, et al. Among authors: orlandi f. J Nucl Med. 2017 Feb;58(2):293-299. doi: 10.2967/jnumed.116.176636. Epub 2016 Sep 8. J Nucl Med. 2017. PMID: 27609789 Free article.

5

NeoBOMB1, a GRPR-Antagonist for Breast Cancer Theragnostics: First Results of a Preclinical Study with [⁶⁷Ga]NeoBOMB1 in T-47D Cells and Tumor-Bearing Mice.

Kaloudi A, Lymperis E, Giarika A, Dalm S, Orlandi F, Barbato D, Tedesco M, Maina T, de Jong M, Nock BA. Kaloudi A, et al. Among authors: orlandi f. Molecules. 2017 Nov 11;22(11):1950. doi: 10.3390/molecules22111950. Molecules. 2017. PMID: 29137110 Free PMC article.

6

The Balance Between the Therapeutic Efficacy and Safety of [¹⁷⁷Lu]Lu-NeoB in a Preclinical Prostate Cancer Model.

Verhoeven M, Haeck J, de Blois E, Orlandi F, Barbato D, Tedesco M, Konijnenberg M, Dalm SU. Verhoeven M, et al. Among authors: orlandi f. Mol Imaging Biol. 2024 Feb;26(1):114-123. doi: 10.1007/s11307-023-01851-4. Epub 2023 Aug 28. Mol Imaging Biol. 2024. PMID: 37640941 Free PMC article.

7

In Vivo Biodistribution and Efficacy Evaluation of NeoB, a Radiotracer Targeted to GRPR, in Mice Bearing Gastrointestinal Stromal Tumor.

Montemagno C, Raes F, Ahmadi M, Bacot S, Debiossat M, Leenhardt J, Boutonnat J, Orlandi F, Barbato D, Tedesco M, Ghezzi C, Perret P, Broisat A. Montemagno C, et al. Among authors: orlandi f. Cancers (Basel). 2021 Mar 2;13(5):1051. doi: 10.3390/cancers13051051. Cancers (Basel). 2021. PMID: 33801382 Free PMC article.

8

Erythropoietin Pretreatment of Transplanted Endothelial Colony-Forming Cells Enhances Recovery in a Cerebral Ischemia Model by Increasing Their Homing Ability: A SPECT/CT Study.

Garrigue P, Hache G, Bennis Y, Brige P, Stalin J, Pellegrini L, Velly L, Orlandi F, Castaldi E, Dignat-George F, Sabatier F, Guillet B. Garrigue P, et al. Among authors: orlandi f. J Nucl Med. 2016 Nov;57(11):1798-1804. doi: 10.2967/jnumed.115.170308. Epub 2016 Sep 8. J Nucl Med. 2016. PMID: 27609786 Free article.

9

Histologic tau lesions and magnetic resonance imaging biomarkers differ across two progressive supranuclear palsy variants.

Orlandi F, Carlos AF, Ali F, Clark HM, Duffy JR, Utianski RL, Botha H, Machulda MM, Stephens YC, Schwarz CG, Senjem ML, Jack CR, Agosta F, Filippi M, Dickson DW, Josephs KA, Whitwell JL. Orlandi F, et al. Brain Commun. 2024 Apr 5;6(2):fcae113. doi: 10.1093/braincomms/fcae113. eCollection 2024. Brain Commun. 2024. PMID: 38660629 Free PMC article.

10

Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma.

Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Symeonides SN, Hajek J, Chang YH, Lee JL, Sarwar N, Haas NB, Gurney H, Sawrycki P, Mahave M, Gross-Goupil M, Zhang T, Burke JM, Doshi G, Melichar B, Kopyltsov E, Alva A, Oudard S, Topart D, Hammers H, Kitamura H, McDermott DF, Silva A, Winquist E, Cornell J, Elfiky A, Burgents JE, Perini RF, Powles T; KEYNOTE-564 Investigators. Choueiri TK, et al. N Engl J Med. 2024 Apr 18;390(15):1359-1371. doi: 10.1056/NEJMoa2312695. N Engl J Med. 2024. PMID: 38631003 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

412 results

Search Page